Income Taxes (Details Narrative) (USD $)	Jul. 31, 2014	Jul. 31, 2013	Jul. 31, 2012
Pretax losses arising from domestic operations	$ 1,274,619	$ (8,025,582)	$ (8,040,033)
Pretax losses arising from foreign operations	1,276,036	528,741	1,450,244
Generex Biotechnology Corporation
NOL carryforwards, expiring through 2033	202,000,000
Generex Pharmaceuticals, Inc
NOL carryforwards, expiring through 2033	44,000,000
Antigen Express, Inc
NOL carryforwards, expiring through 2033	$ 25,000,000

Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32621-109319

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32632-109319

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 740

-SubTopic 10

-Section 25

-Paragraph 20

-Subparagraph (b)

-URI http://asc.fasb.org/extlink&oid=29652012&loc=d3e28680-109314

Name:	us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant